Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMW NASDAQ:DRTSW NASDAQ:SXTPW NASDAQ:TVGNW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01-2.2%$0.01$0.00▼$0.05N/AN/A26,037 shs9,010 shsDRTSWAlpha Tau Medical$2.00-15.6%$1.51$0.20▼$2.99N/AN/A55,643 shs18,187 shsSXTPW60 Degrees Pharmaceuticals$0.04-0.3%$0.05$0.03▼$0.16N/AN/A12,420 shs1,100 shsTVGNWTevogen Bio$0.04-1.2%$0.04$0.03▼$0.08N/AN/A132,121 shs311,863 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-2.24%-2.24%-18.13%+1.55%-37.62%DRTSWAlpha Tau Medical-15.61%-28.57%+110.75%+104.62%+773.36%SXTPW60 Degrees Pharmaceuticals-0.26%-1.78%-16.09%-3.50%-35.45%TVGNWTevogen Bio+6.41%+6.14%+16.57%+18.91%-30.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01-2.2%$0.01$0.00▼$0.05N/AN/A26,037 shs9,010 shsDRTSWAlpha Tau Medical$2.00-15.6%$1.51$0.20▼$2.99N/AN/A55,643 shs18,187 shsSXTPW60 Degrees Pharmaceuticals$0.04-0.3%$0.05$0.03▼$0.16N/AN/A12,420 shs1,100 shsTVGNWTevogen Bio$0.04-1.2%$0.04$0.03▼$0.08N/AN/A132,121 shs311,863 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-2.24%-2.24%-18.13%+1.55%-37.62%DRTSWAlpha Tau Medical-15.61%-28.57%+110.75%+104.62%+773.36%SXTPW60 Degrees Pharmaceuticals-0.26%-1.78%-16.09%-3.50%-35.45%TVGNWTevogen Bio+6.41%+6.14%+16.57%+18.91%-30.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMWApollomics 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ATVGNWTevogen Bio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMWApollomics$8.50MN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/AN/ATVGNWTevogen BioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMWApollomicsN/AN/AN/AN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)SXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ATVGNWTevogen BioN/AN/AN/AN/AN/AN/AN/AN/A8/13/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMWApollomicsN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATVGNWTevogen BioN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMWApollomicsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ATVGNWTevogen BioN/AInsider OwnershipCompanyInsider OwnershipAPLMWApollomicsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ATVGNWTevogen BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMWApollomics59N/AN/ANot OptionableDRTSWAlpha Tau Medical80N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableTVGNWTevogen Bio17N/AN/AN/ATVGNW, SXTPW, DRTSW, and APLMW HeadlinesRecent News About These CompaniesTevogen Bio (TVGNW) Projected to Post Quarterly Earnings on WednesdayMay 27, 2026 | americanbankingnews.comTevogen Bio Holdings Inc. Outlines Strategic Growth and Advancements in AI-Driven Healthcare SolutionsAugust 11, 2025 | quiverquant.comQTevogen Bio Holdings Inc. Secures $1 Million Funding to Advance Tevogen.AI Drug Discovery InitiativeAugust 7, 2025 | quiverquant.comQTevogen Bio Holdings Inc. Secures $1 Million Grant to Advance AI-Driven Drug Discovery InitiativeAugust 1, 2025 | quiverquant.comQTevogen Bio Holdings Inc. Announces Opening of Expanded Headquarters Funded by CEO's Personal ContributionJuly 10, 2025 | quiverquant.comQTevogen Bio Grants Restricted Stock to CEOJuly 10, 2025 | tipranks.comTevogen Bio Holdings Enters $50M Sales AgreementJuly 3, 2025 | tipranks.comMedia Sentiment Over TimeTVGNW, SXTPW, DRTSW, and APLMW Company DescriptionsApollomics NASDAQ:APLMW$0.01 0.00 (-2.24%) As of 06/5/2026 11:05 AM EasternApollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.Alpha Tau Medical NASDAQ:DRTSW$2.00 -0.37 (-15.61%) Closing price 06/5/2026 03:54 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 06/5/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.04 0.00 (-0.26%) As of 06/5/2026 03:46 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.Tevogen Bio NASDAQ:TVGNW$0.04 0.00 (-1.19%) As of 06/5/2026 03:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
